Remove Office Remove Partnerships Remove Safety
article thumbnail

U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN

The Dermatology Digest

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile. Every treatment approval is hard-won, built on research, persistence, and partnership.

article thumbnail

Dermata, Revance Partner to Study Topical Application of Xyngari With Daxxify for Primary Axillary Hyperhidrosis

The Dermatology Digest

The Companies intend to first evaluate Xyngari with for the topical treatment of primary axillary hyperhidrosis and may explore additional indications through a broader partnership in the future.

article thumbnail

Touchdown: Novartis Named First-ever Corporate Pharmaceutical Partner of the NFL

The Dermatology Digest

The partnership aims to empower football fans everywhere to make proactive decisions about their health, better understand screening guidelines and create a playbook for a healthier future. Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL).

article thumbnail

La Roche-Posay and the Edge Launch Immersive Color Exhibit in NYC

The Dermatology Digest

Whether it’s your first visit to the city or an annual tradition, SHADES at Edge offers a fresh, imaginative way to take in the 360 views of our iconic skyline like never before,” says Francesca Merlino, Chief Commercial Officer at Hudson Yards Experiences, in a news release.

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

“We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech. This launch symbolizes the robustness of our platform, the value of our partnership with STADA, and our collective focus on the importance of biosimilars.”

article thumbnail

Biosimilar News: FDA Approves Simlandi as Third Interchangeable Humira Biosimilar

The Dermatology Digest

Eric Hughes, Executive Vice President Global R&D and Chief Medical Officer at Teva, in a news release. This approval marks an important milestone for Teva and Alvotech’s partnership to collaborate on seven biosimilars and expand the availability, access, and uptake of biosimilars in the U.S.”

Safety 36
article thumbnail

FDA Approves Merz Aesthetics’ Xeomin for Smoothing Moderate to Severe Upper Facial Lines

The Dermatology Digest

. “XEOMIN is the first and only FDA-approved neurotoxin for the simultaneous treatment of upper facial lines (forehead lines, frown lines and crow’s feet lines),” says Dr. Samantha Kerr, Chief Scientific Officer at Merz Aesthetics, in a news release.

Facials 36